Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3

Long noncoding RNA (lncRNA) have critical roles in various pathophysiological processes, and are frequently dysregulated in many diseases, particularly in cancer. The lncRNA glypican 3 antisense transcript 1 (GPC3‐AS1) has been reported to be a potential biomarker for hepatocellular carcinoma (HCC) screening. However, the exact biological functions of GPC3‐AS1 in HCC, and its roles and regulation mechanisms regarding GPC3 are still unknown. In this study, we observed a significant upregulation of GPC3‐AS1 in HCC. Increased expression of GPC3‐AS1 was associated with α‐fetoprotein, tumor size, microvascular invasion, encapsulation, Barcelona Clinic Liver Cancer stage, and worse prognosis of HCC patients. Furthermore, we found that GPC3‐AS1 physically associated with P300/CBP‐associated factor and recruited it to the GPC3 gene body region, consequently inducing an increase in euchromatic histone marks and activating GPC3 transcription. GPC3‐AS1 expression was strongly correlated with GPC3 in HCC tissues. Gain‐of‐function and loss‐of‐function analyses showed that GPC3‐AS1 overexpression enhanced HCC cell proliferation and migration in vitro and xenograft tumor growth in vivo. GPC3‐AS1 knockdown inhibited HCC cell proliferation and migration. Moreover, the effects of GPC3‐AS1 on HCC cell proliferation and migration were dependent on the upregulation of GPC3. Collectively, our studies indicate that GPC3‐AS1 significantly promotes HCC progression via epigenetically activating GPC3, and identifies GPC3‐AS1 as a potential therapeutic target for HCC.

[1]  Z. Bi,et al.  Long noncoding RNA FGFR3-AS1 promotes osteosarcoma growth through regulating its natural antisense transcript FGFR3 , 2016, Molecular Biology Reports.

[2]  Leng Han,et al.  The LINK-A lncRNA Activates Normoxic HIF1α Signaling in Triple-negative Breast Cancer , 2016, Nature Cell Biology.

[3]  H. Li,et al.  Upregulation of long noncoding RNA ZEB1-AS1 promotes tumor metastasis and predicts poor prognosis in hepatocellular carcinoma , 2015, Oncogene.

[4]  R. Shiekhattar,et al.  The many faces of long noncoding RNAs , 2015, The FEBS journal.

[5]  Feng Xie,et al.  Investigation of serum lncRNA-uc003wbd and lncRNA-AF085935 expression profile in patients with hepatocellular carcinoma and HBV , 2015, Tumor Biology.

[6]  G. Lou,et al.  Long noncoding RNA CCHE1 promotes cervical cancer cell proliferation via upregulating PCNA , 2015, Tumor Biology.

[7]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[8]  J. Collins.  Long noncoding RNAs and hepatocellular carcinoma. , 2015, Gastroenterology.

[9]  S. Dhanasekaran,et al.  The landscape of long noncoding RNAs in the human transcriptome , 2015, Nature Genetics.

[10]  Mitchell Ho,et al.  Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican‐3 for liver cancer therapy , 2014, Hepatology.

[11]  Shuhan Sun,et al.  Antisense long non-coding RNA PCNA-AS1 promotes tumor growth by regulating proliferating cell nuclear antigen in hepatocellular carcinoma. , 2014, Cancer letters.

[12]  Shuhan Sun,et al.  A long noncoding RNA activated by TGF-β promotes the invasion-metastasis cascade in hepatocellular carcinoma. , 2014, Cancer cell.

[13]  Vijay Kumar,et al.  Combinatorial action of transcription factors orchestrates cell cycle‐dependent expression of the ribosomal protein genes and ribosome biogenesis , 2014, The FEBS journal.

[14]  Se Jin Park,et al.  Oncogenic potential of CK2α and its regulatory role in EGF‐induced HDAC2 expression in human liver cancer , 2014, The FEBS journal.

[15]  Mitchell Ho,et al.  Glypican‐3 antibodies: A new therapeutic target for liver cancer , 2014, FEBS letters.

[16]  A. Fatica,et al.  Long non-coding RNAs: new players in cell differentiation and development , 2013, Nature Reviews Genetics.

[17]  A. Diehl,et al.  NAFLD, NASH and liver cancer , 2013, Nature Reviews Gastroenterology &Hepatology.

[18]  J. Filmus,et al.  Glypican‐3: a marker and a therapeutic target in hepatocellular carcinoma , 2013, The FEBS journal.

[19]  X. Wang,et al.  Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma , 2013, Proceedings of the National Academy of Sciences.

[20]  Shuhan Sun,et al.  Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma. , 2013, Carcinogenesis.

[21]  P. Philip,et al.  First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients with Advanced Hepatocellular Carcinoma , 2013, Clinical Cancer Research.

[22]  Piero Carninci,et al.  Long non-coding antisense RNA controls Uchl1 translation through an embedded SINEB2 repeat , 2012, Nature.

[23]  H. Soares,et al.  The Expression of Tubulin Cofactor A (TBCA) Is Regulated by a Noncoding Antisense Tbca RNA during Testis Maturation , 2012, PloS one.

[24]  R. Luo,et al.  MiR‐219‐5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican‐3 , 2012, FEBS letters.

[25]  M. Kojima,et al.  Glypican‐3 expression is correlated with poor prognosis in hepatocellular carcinoma , 2009, Cancer science.

[26]  S. Giulini,et al.  MicroRNA‐23b mediates urokinase and c‐met downmodulation and a decreased migration of human hepatocellular carcinoma cells , 2009, The FEBS journal.

[27]  P. Tandon,et al.  Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[28]  C. Ponting,et al.  Evolution and Functions of Long Noncoding RNAs , 2009, Cell.

[29]  K. Kinzler,et al.  The Antisense Transcriptomes of Human Cells , 2008, Science.

[30]  H. Aburatani,et al.  Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. , 2008, Cancer research.

[31]  J. Komorowski,et al.  Kcnq1ot1 antisense noncoding RNA mediates lineage-specific transcriptional silencing through chromatin-level regulation. , 2008, Molecular cell.

[32]  T. Morgan,et al.  Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of β-secretase , 2008, Nature Medicine.

[33]  A. Feinberg,et al.  Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA , 2008, Nature.

[34]  Howard Y. Chang,et al.  Functional Demarcation of Active and Silent Chromatin Domains in Human HOX Loci by Noncoding RNAs , 2007, Cell.

[35]  Wen Shi,et al.  Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. , 2003, Gastroenterology.

[36]  C. Méndez-Vidal,et al.  Wrap53, a Natural p53 Antisense Transcript Required for p53 Induction upon DNA Damage. , 2016, Molecular cell.

[37]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[38]  Junfang Ji,et al.  Title MicroRNA expression, survival, and response to interferon in liver cancer , 2009 .